New drug duo aims to outsmart resistant lung cancer
NCT ID NCT05017025
Summary
This trial is testing whether adding a new drug called LY3295668 to an existing lung cancer drug (osimertinib) can help control cancer that has stopped responding to standard treatment. It involves 32 adults with a specific type of advanced lung cancer (EGFR-mutant non-small cell) that has spread. The main goals are to find a safe dose for the combination and see if it can slow or stop cancer growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIB LUNG CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.